熱門資訊> 正文
Xenetic Biosciences报告第二季度业绩
2025-08-13 22:16
- Xenetic Biosciences press release (NASDAQ:XBIO): Q2 Net loss for the quarter ended June 30, 2025 was approximately $0.7 million.
- Research & development expenses for the three months ended June 30, 2025 decreased by approximately $277,000, or 29.7%, to approximately $0.7 million from $0.9 million in the comparable quarter in 2024. General and administrative expenses for the three months ended June 30, 2025 decreased by approximately $472,000, or 41.8%, to approximately $0.7 million from approximately $1.1 million in the comparable quarter in 2024.
More on Xenetic Biosciences
- Seeking Alpha’s Quant Rating on Xenetic Biosciences
- Historical earnings data for Xenetic Biosciences
- Financial information for Xenetic Biosciences
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
